Senseonics Joins Sequel to Bring 1-Year CGM to Insulin Dosing System

Senseonics and Sequel Med Tech have announced a partnership to integrate the Eversense 365 continuous glucose monitor (CGM)—approved for year-long use—into Sequel’s Twiist automated insulin dosing (AID) system. This marks the first time Senseonics’ implantable CGM will be compatible with an insulin pump, building on the FDA’s 2023 clearance that allows Eversense to function as an integrated CGM without routine fingerstick calibration. The system, which uses Tidepool’s AID app, is expected to launch in the third quarter of 2025.

While analysts expect limited short-term commercial impact, the collaboration represents a significant step in increasing the interoperability of Eversense technology. Sequel previously partnered with Abbott to integrate the Libre 3 Plus with Twiist, and now becomes the first to support Senseonics' implantable sensor. Senseonics’ leadership sees this kind of integration as both a product validation and a long-term growth driver, especially as the company continues to target a broader diabetes population beyond pump users.